RecruitingPhase 2NCT04645602

Merck IIT: RRP Pembro and Lenvatinib

A Pilot Study of Lenvatinib in Combination With Pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis Patients

Sponsor

Yale University

Enrollment

20 participants

Start Date

Jul 18, 2025

Study Type

INTERVENTIONAL

Conditions

Pulmonary Disease Recurrent Respiratory Papillomatosis Human Papilloma Virus

Summary

This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Lenvatinib and a drug called Pembrolizumab for people with human papilloma virus, pulmonary disease, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.